3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
34
Lymphoma, Non-Hodgkin
31
Lymphoma
20
Lymphoma, Mantle-Cell
18
Multiple Myeloma
17
Lymphoma, Follicular
16
Lymphoma, Large B-Cell, Diffuse
14
Hodgkin Disease
11
Lymphoma, B-Cell, Marginal Zone
9
Recurrence
6
Leukemia
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Waldenstrom Macroglobulinemia
4
Neoplasms, Plasma Cell
4
Lymphoma, B-Cell
3
Leukemia, Lymphoid
3
Hematologic Diseases
3
Burkitt Lymphoma
3
Small Cell Lung Carcinoma
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Hairy Cell
2
Interventions
blinatumomab
6
Cyclophosphamide
5
Rituximab
4
Tacrolimus
3
ponatinib
2
fludarabine
2
denileukin diftitox
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Everolimus
2
Etoposide
2
Doxorubicin
2
Darbepoetin alfa
2
Cytarabine
2
Busulfan
2
Brentuximab Vedotin
2
Antilymphocyte Serum
2
Alemtuzumab
2
tetulomab tetraxetan lu-177
1
ruxolitinib
1
pembrolizumab
1
pegaspargase
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
ferrous sulfate
1
ferric gluconate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoproliferative Disorders
×
Bendamustine Hydrochloride
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts